<DOC>
	<DOCNO>NCT00892827</DOCNO>
	<brief_summary>Chronic lymphocytic leukemia ( CLL ) , indolent disease mature-looking B lymphocytes , common leukemia Israel Western world . The disease associate considerable morbidity mortality , currently incurable . Rituximab ( Mabthera ) chimeric monoclonal antibody direct CD20 antigen , present exclusively B lymphocytes . Treatment Rituximab widely use indolent B cell malignancy . However , administration Rituximab CLL patient yield less successful result indolent B cell malignancy , even respond patient may become refractory . We hypothesize abnormality complement system identify CLL underlie suboptimal response Rituximab , since complement-dependent cell cytotoxicity major mechanism Rituximab action . Following patient consent Institutional Review Board approval , standard-dose Rituximab ( 375 mg/m2 ) administer , precede 2 unit FFP . This treatment repeat every 1-2 week 4-6 cycle . The clinical laboratory parameter , well adverse drug event , monitor .</brief_summary>
	<brief_title>Combined Treatment With Fresh Frozen Plasma Rituximab ( Mabthera ) Patients With Advanced Refractory Chronic Lymphocytic Leukemia</brief_title>
	<detailed_description>Indolent B cell Non-Hodgkin 's lymphoma patient show good response Rituximab , administer either alone preferably standard chemotherapy . The response Rituximab patient CLL inferior comparison indolent B cell malignancy . The therapeutic approach combine treatment Rituximab fresh frozen plasma ( FFP ) use u first one case follow impressive response - additional 2 patient , undertaken basis two observation . We assume , addition FFP Rituximab treatment would increase and/or restore efficacy Rituximab advance CLL patient resistant therapy correct abnormal complement system thus allow improve complement activation increase anti-leukemic activity . The major aim study : ( 1 ) To establish efficacy combination FFP RTX determine response rate . ( 2 ) To elucidate effector mechanism responsible efficacy FFP-Rituximab combination . The secondary aim study ( 1 ) To establish response duration combination FFP RTX determine time progression . time treatment ( 2 ) To determine safety combine treatment . The study design single-arm , phase II study evaluate efficacy safety combine treatment FFP RTX advance refractory chronic lymphocytic leukemia , along analysis complement system associate parameter .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Complement System Proteins</mesh_term>
	<criteria>Diagnosis : advanced ( Rai stage â‰¥2 symptomatic stage 1 ) CLL Resistant relapse treatment Fludarabine and/or Rituximab Lymphocyte count 100,000 cells/mcl high . Time last antileukemia treatment : 1 month Age : male female 18 year age . Informed consent obtain Lack one inclusion criterion Known sensitivity human plasma Known sensitivity Rituximab ( Mabthera ) Active second malignant disease ( nonmelanoma skin cancer ) &lt; 2 year prior study Active infectious disease &lt; 1 month prior study Hepatitis B serology : Hepatitis B surface antigen positive Renal function : Creatinin &gt; 3 mg/dL Liver function : Liver enzymes less x2 normal value Performance status : ECOG performance status 4 Use investigational agent &lt; 30 day ago Known poor adherence treatment plan</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2010</verification_date>
	<keyword>Rituximab</keyword>
	<keyword>Mabthera</keyword>
	<keyword>FFP</keyword>
	<keyword>Fresh Frozen Plasma</keyword>
	<keyword>CLL</keyword>
	<keyword>Complement</keyword>
	<keyword>Response</keyword>
	<keyword>Overall response rate FFP+Rituximab combine therapy</keyword>
	<keyword>Analysis complement activation pathways prior ,</keyword>
	<keyword>study treatment .</keyword>
	<keyword>Time disease progression</keyword>
	<keyword>Time re-treatment ( See Appendix I ) .</keyword>
	<keyword>Safety combination treatment FFP RTX .</keyword>
</DOC>